Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erwinia asparaginase in elderly Ph-negative ALL
NCT02647190Phase 1Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2016
- Primary completion
- Jun 2017
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of asparaginase escherichia coli in acute lymphoblastic leukemia (ALL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose Limiting Toxicity at 6 weeks. Planned start Jan 2016; status: withdrawn.
02
Drugs
asparaginase escherichia coli
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02647190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02647190.